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Abstract In contrast to typical mammals, the chicken MHC
(the BF-BL region of the B locus) has strong genetic asso-
ciations with resistance and susceptibility to infectious path-
ogens as well as responses to vaccines. We have shown that
the chicken MHC encodes a single dominantly expressed
class I molecule whose peptide-binding motifs can deter-
mine resistance to viral pathogens, such as Rous sarcoma
virus and Marek’s disease virus. In this report, we examine
the response to a molecular defined vaccine, fp-IBD1,
which consists of a fowlpox virus vector carrying the VP2
gene of infectious bursal disease virus (IBDV) fused with β-
galactosidase. We vaccinated parental lines and two back-
cross families with fp-IBD1, challenged with the virulent
IBDV strain F52/70, and measured damage to the bursa. We
found that the MHC haplotype B15 from line 15I confers no
protection, whereas B2 from line 61 and B12 from line C
determine protection, although another locus from line 61
was also important. Using our peptide motifs, we found that
many more peptides from VP2 were predicted to bind to the
dominantly expressed class I molecule BF2*1201 than
BF2*1501. Moreover, most of the peptides predicted to bind
BF2*1201 did in fact bind, while none bound BF2*1501.
Using peptide vaccination, we identified one B12 peptide
that conferred protection to challenge, as assessed by bursal
damage and viremia. Thus, we show the strong genetic
association of the chicken MHC to a T cell vaccine can be
explained by peptide presentation by the single dominantly
expressed class I molecule.
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Introduction
The MHC is the region with the most disease associations in
the human genome, but by far the greatest number and
strongest associations are with autoimmune diseases. In
contrast, the chicken MHC has many associations with
resistance and susceptibility to infectious disease (reviewed
in Kaufman 2008). The chance discovery that a single
classical class I and a single classical class II molecule are
expressed at high levels in common chicken MHC
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haplotypes led us to propose the hypothesis that the BF-BL
region of the chicken is a “minimal essential MHC”. By
this, we meant the region responsible for the major
histocompatibility reactions that contains single domi-
nantly expressed classical class I and II molecules
whose properties determine the immune response (Kaufman
et al. 1995). At the time of this proposal, we also found
that there were actually two class I genes with at least
one TAP gene in between, which led us to propose that
co-evolution with the antigen-presenting genes was re-
sponsible for the dominantly expressed class I gene
(Kaufman et al. 1995). Since that time, much evidence
has been collected to support these views (Jacob et al. 2000;
Kaufman et al. 1999a; Koch et al. 2007; Salomonsen et al.
2003; Shaw et al. 2007; Walker et al. 2011; Wallny et al.
2006); including the fact that many if not most non-
mammalian vertebrates (as well as at least one marsupial,
Belov et al. 2007) have these salient features of the chicken
MHC, including the strong associations of the MHC with
infectious disease (Grimholt et al. 2003; reviewed in Kaufman
1999, 2008, 2010).
However, there is some confusion in the literature
over whether the chicken MHC really is small and
simple or is actually large and complicated. Many in-
vestigators, including ourselves, have characterised
genes located on the chicken MHC microchromosome
that in other animals are found in regions of the MHC,
adjacent to the MHC, or in MHC paralogous regions
(Afanassieff et al. 2001; Briles et al. 1993; Guillemot et
al. 1988; Kaufman et al. 1999a; Maruoka et al. 2005;
Miller et al. 1994a, b, 1996, 2005; Rogers et al. 2005;
Rogers and Kaufman 2008; Ruby et al. 2005;
Salomonsen et al. 2003, 2005; Shiina et al. 2007). This
has led to an alternative view that the chicken MHC is
in fact very large and complex, containing many genes
located in at least two separate regions, called MHC-B
and MHC-Y (Afanassieff et al. 2001; Delany et al.
2009; Miller et al. 1996; Solinhac et al. 2010). We have
concluded that the difference in these views lies in
emphasis (Kaufman et al. 1999b). The minimal essential
MHC concept as originally stated (Kaufman et al. 1995,
1999a) defines an MHC based on function, a region of
the genome containing the classical polymorphic class I
and class II genes responsible for strong histocompati-
bility reactions (that is, a major histocompatibility com-
plex). The alternative view defines the MHC as a
genomic region, with any gene ever found in or adja-
cent to an MHC becoming part of that MHC, and with
the term itself becoming a genetic acronym rather than
a functional definition. In our view, the minimal essen-
tial MHC is the selected and conserved unit of classical
MHC molecules (which we call "the classical MHC"
and which has also been dubbed "the core MHC",
Shiina et al. 2007), around which other genes come
and go as part of the MHC syntenic region (which
has also been referred to as "the extended MHC").
Whichever way one wishes to view the chicken MHC,
there is no doubt that there is a small and simple region (the
BF-BL region) which contains the essential polymorphic
components of antigen presentation by classical MHC mole-
cules, and that this close proximity of classical MHC genes
with the polymorphic genes that process and load their pep-
tides is a feature of many, if not most, non-mammalian verte-
brates. It therefore remains interesting and important to test to
what extent the single dominantly expressed MHC molecules
of the chicken MHC can explain the strong genetic associa-
tions with disease resistance and vaccine responses.
We have determined simple peptide motifs for certain
chicken class I molecules based on the peptides eluted from
chicken class I molecules isolated from spleen and blood
cells (Kaufman et al. 1995; Koch et al. 2007; Wallny et al.
2006). There are strong MHC associations for resistance and
susceptibility to the pathogens Rous sarcoma virus (RSV)
and Marek’s disease virus (MDV), and we found many
more peptides predicted to bind class I molecules from
resistant than from susceptible chicken lines. We used cell
binding and assembly assays to determine which of the
peptides predicted by the simple motifs would actually bind
the class I molecules. For RSV, we found that vaccination
with a single identified peptide would eliminate disease
(Hofmann et al. 2003). Since then, the utility of these motifs
has been confirmed by other researchers for the pathogen
avian influenza virus (Hou et al. 2012; Reemers et al. 2012).
In this paper, we wish to examine a poultry vaccine.
Gumburo disease is caused by an immunosuppressive
birnavirus called infectious bursal disease virus (IBDV) that
infects and kills cells of the B lineage in chickens (reviewed
in Ingrao et al. 2013; Mahgoub et al. 2012; Müller et al.
2003, 2012; Schat and Skinner 2008; van den Berg 2000).
There is biphasic age-related resistance. Chicks up to
2 weeks old frequently survive, although the bursa is rav-
aged, the B cell system is depleted, and thereafter birds do
not respond well to vaccines. There follows a period of
susceptibility, peaking at 3–4 weeks of age, during
which a virulent virus will kill birds. With time, an
increasing resistance to mortality develops, although
the birds may still suffer immunosuppression and mor-
bidity, evidenced by weight loss or reduction in egg-
laying. The disease is controlled mainly by vaccination
in ovo, vaccination of chicks or vaccination of laying
hens, usually with an attenuated live viral vaccine and
often followed by an inactivated vaccine, both of which
raise antibodies mostly to the major capsid protein, viral
protein 2 (VP2). However, both antigenic variation and
increases in virulence of the virus have been reported,
so Gumboro disease is still an economic concern for the
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poultry industry, and various approaches to vaccines
continue to be developed.
An early experimental vaccine called fp-IBD1 was creat-
ed with the VP2 as a fusion protein with β-galactosidase in a
fowlpox virus vector (Bayliss et al. 1991). This vaccine
protects some experimental chicken lines but not others
(Shaw and Davison 2000). In particular, line 61
(homozygous for MHC haplotype B2) and line C-B12
(homozygous for B12) were shown to be protected by
fp-IBD1, while line 15I (homozygous for B15) was not.
The protection in line 61 was partially conferred by the
fowlpox virus vector alone, while the protection in line
C-B12 was not. In both cases, the protection was found
not to be due to antibodies, which suggested the in-
volvement of T cells recognising MHC molecules
(Shaw and Davison 2000). In this report, we extend
this work to examine the contribution of the chicken
MHC to protection by the vaccine fp-IBD1.
Materials and methods
Animals The histories of the chicken lines 61 (B2),
C-B4 (B4), C-B12 (B12) and 15I (B15), bred and
maintained under specific pathogen-free conditions at
the Institute for Animal Health (Compton, UK), have
been described (Jacob et al. 2000). Chicks were trans-
ferred at 1 day of age to isolation accommodation
equipped with high-efficiency particle air filters. All
procedures were carried out in accordance the United
Kingdom Animals (Scientific Procedures) Act and were
subject to local ethical review.
Backcross and mapping F1 crosses were produced
between C-B12 and 15I birds and between 61 and 15I
birds. Laying F1 hens were inseminated with semen
from 15I birds to produce backcross progeny. Typing
by microsatellite analysis (Khatib et al. 1993) yielded
35 MHC heterozygous and 25 MHC homozygous prog-
eny from the 15I x (61×15I) backcross, and 24 MHC
heterozygous and 25 MHC homozygous progeny from
the 15I×(C-B12×15I) backcross. Together with 30 birds of
each parental line, all chicks were vaccinated with fp-IBD1
and challenged with F52/70 as described below.
Fowlpox vectored vaccination The fowlpox virus recom-
binant vaccine fp-IBD1 encodes the VP2 sequence of
the virulent IBVD virus F52/70 as a β-galactosidase
fusion protein (Bayliss et al. 1991) and was produced
by tissue culture passage on chick embryo fibroblasts as
previously described (Shaw and Davidson 2000). Chicks
were vaccinated at 1 and 3 weeks of age with 107
plaque-forming units fp-IBD1 in a total volume of
50 μl. The vaccine was dropped onto a section of the wing
web, and the skin punctured 30 times with a 25-gauge needle.
Local inflammation was evident at the site of scarification
within 2 days and resolved shortly after.
Challenge virus and infection IBDV F52/70 was propagat-
ed in vivo, and the active concentration of virus was assayed
to determine egg infectious dose (EID) as previously de-
scribed (Butter et al. 2003; Van Loon et al. 1994). Chicks
were challenged with 10 EID50 IBDV F52/70 in a total
volume of 100 μl by the intranasal route, 10 days after the
second vaccination with either peptide (see below) or
fp-IBD1 (see above).
Peptide prediction As in Wallny et al. (2006), peptides were
predicted from VP2 sequence derived from F52/70 (acces-
sion number D00869.2) by using the GCG program
FINDPATTERNS (Anonymous 1991) and relaxed motifs
for the dominantly expressed class I molecules of two
chicken haplotypes. These relaxed motifs allow both
octamers and nonamers with all residues found in anchor
positions by pool sequencing (Wallny et al. 2006). The
motifs are denoted for FINDPATTERNS by the notation
xxx(x,xx)(V,I)xx(V,L,I) for B12 and xRxxxx(x,xx)Y for B15,
in which x denotes any amino acid, single capital letters refer to
amino acids in the IUPAC single letter code and parentheses
enclose alternatives, so (x,xx) means either one or two amino
acids, and (V,L,I) means either valine, leucine or isoleucine.
Peptides were synthesized by fluorenylmethoxycarbonyl chem-
istry, purified by HPLC, and resuspended at 1 mg/ml in PBS
(with up to 1 % DMSO).
Stabilisation assay As in Wallny et al. (2006), chicken
peripheral blood lymphocytes without thrombocytes were
cultured (107 cells per ml at 40 °C, 5 % CO2) overnight in
Dulbecco’s modified minimal Eagle’s medium with
0.5 mg/ml bovine serum albumin (BSA) and with or without
1 mM synthetic peptides (in triplicate). Then, cells were
washed (phosphate-buffered saline, 0.5 % BSA, 0.1 %
NaN3), and flow cytometric analysis using a monoclonal
antibody against chicken β2-microglobulin (F21-21, Skjødt
et al. 1986) followed by FITC-conjugated goat anti-mouse
IgG (Silenus, Paris) was performed, gating on small
lymphocytes.
Assembly assay As in Koch et al. (2007), inclusion bodies
from β2m cDNA sequence (encoding the mature protein
without a signal sequence but beginning with a start codon
for methionine) and for BF2*1201 cDNA (residues 1–270
of the mature protein without a signal sequence but with a
codon for Met added at the beginning) in pET22b(+) were
isolated from BL21 (λDE3) pLysS Rosetta cells, and
dissolved in 8 M urea, 10 mM 2-mercaptoethanol,
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100 mM NaH2PO4, 10 mM TrisCl, pH 8. Small-scale as-
sembly assays were carried out at 4 °C in 1 ml refold buffer
[100 mM TrisCl pH 8.2, 400 mM arginine, 0.5 mM oxidized
gluta th ione, 5 mM reduced gluta th ione, 2 mM
ethylenediamine tetraacetic acid, 0.1 mM 4-(2 aminoethyl)
benzenesulfonyl fluoride (Pefablock, Sigma)]. The peptide,
β2m and heavy chain were added slowly with vigorous
stirring in a molar ratio of 10:2:1 (usually around
1:24:31 μg in 1 ml). After 18–30 h, FPLC size exclusion
chromatography (AKTA, Pharmacia) with a HiLoad 26/60
Superdex 75 column (Pharmacia) in 0.15 M NaCl, 0.1 M
TrisCl pH 8.2 was used to separate aggregates, monomers,
heavy chains, β2m, peptides and smaller molecules.
Peptide vaccination As in Hofmann et al. (2003), 18 mg
L-α-phosphatidylcholine, 2 mg L-α-phosphatidyl-DL-glyc-
erol and 5 mg cholesterol (all components from Sigma) were
suspended in 5 ml chloroform and rotary evaporated under
reduced pressure until a thin lipid film formed on the flask
wall. Residual chloroform was removed by vacuum desic-
cation. Threemilligrams of peptide was dissolved in 1ml PBS
containing 0.4 mg Quil A and 1 mM 2-mercaptoethanol. This
solution was added to the dried lipids and slowly shaken until
the lipids were re-suspended and then equilibrated 30 min at
room temperature. C-B12 chicks were immunised at 1 and
3 weeks of age with 100 μg peptide in 0.2 ml of liposomes per
injection, i.m. into the pectoral muscle. Some other chicks
were not vaccinated, some others were vaccinated with fp-
IBD1 and most chicks were challenged with F52/70 as de-
scribed above. Three were ten birds per group. Blood samples
were taken daily to determine viremia (Moody et al. 2000).
Five days post-infection, the birds were sacrificed, the bursa
dissected, RNA extracted by standard techniques (Staines et
al. 2013) and the remaining tissue prepared for routine wax-
embedded histology.
Assessment of protection Bursal/body weight ratio, bursal
damage score, peak blood viremia and bursal viral load
were used as post-mortem measures of pathology.
Bursal damage score is described elsewhere (Williams
and Davison 2010). Briefly, a histological scoring sys-
tem ranging from 0, representing normal bursal archi-
tecture, to 5, representing complete loss of bursal
architecture, was used to assess bursal histopathology.
All slides were encoded and the scoring carried out
blind, with the identity of the samples unknown. Quan-
titative RT-PCR was performed to determine relative
amounts of VP2 gene transcripts in blood and bursal
samples using the primer-probe combinations previously
described (Moody et al. 2000) and the results
normalised against the expression of 28S RNA, deter-
mined in a duplex reaction with VP2, and presented as
Log2Ro (Butter et al. 2007).
Results
Genetic mapping shows that the chicken MHC is a major
locus for response to fp-IBD1
Given that fp-IBD1 elicits very different levels of protection
in different strains of chicken, we examined whether the
MHC is a major genetic locus in this response. Using the
high responder lines (line 61 homozygous for MHC haplo-
type B2, C-B12 homozygous for B12) and a low responder
line (15I homozygous for B15), we first bred F1 chickens
(61×15I heterozygous for B2/B15, and C-B12×15I hetero-
zygous for B12/B15), then bred two backcross families,
immunised with fp-IBD1, challenged with the virulent
IBDV strain F52/70, and measured damage to the bursa of
Fabricius.
In the first comparison (Fig. 1), the majority of the
chickens of the low responder parental line 15I
(B15/B15) had a high bursal damage score, while nearly
all of the chickens of the high responder parental line
61 (B2/B2) had little or no bursal damage. From the
backcross 15I×F1 (61×15I) family, about one quarter of
the birds had a high bursal damage score, and the rest
had little or no damage. After typing these chickens, we
found that nearly all of the B15/B2 heterozygotes had
little or no damage, but that half of the B15/B15 ho-
mozygotes had little damage and the other half had a
high bursal damage score. Since genes outside of the
MHC should have segregated randomly, this shows that
a single B2 haplotype in a B2/B15 heterozygote chicken
confers protection, which was as much as two B2
haplotypes in a B2/B2 homozygote chicken. However,
there must be another gene outside of the MHC which
confers responsiveness as well since half of the
B15/B15 homozygote chickens were protected. Thus,
there are two genetic loci that confer the responsiveness
found in line 61 chickens.
In the second comparison (Fig. 1), the majority of
the chickens of the low responder parental line 15I
(B15/B15) had a high bursal damage score, while the
majority of the high responder parental line C-B12
(B12/B12) had little or no bursal damage. From the
backcross 15I×F1(C-B12×15I) family, about half of
the birds had a high bursal damage score, while half
had less damage. After typing these chickens, we found
that most of the B15/B15 homozygote chickens had
high bursal damage score, but most of the B12/B15
heterozygote chickens had a moderate bursal damage
score. Since genes outside of the MHC should have
segregated randomly, this shows that a single B12 hap-
lotype in a B12/B15 heterozygote chicken confers about
half as much protection as two B12 haplotypes in a
B12/B12 homozygote chicken. Thus, there is one major
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genetic locus that confers responsiveness found in line
C-B12 chickens which is the MHC, but two copies of
the C-B12 haplotype are necessary for the highest level
of protection under these circumstances.
Binding and assembly assays show that the MHC-
determined response to fp-IBD1 correlates with the peptides
predicted to bind the MHC class I molecule
Given that the fp-IBD1 vaccine contains IBDV VP2 protein
as a fusion protein with β-galactosidase and that the
mechanism of protection does not involve antibodies, it
seemed most likely that the response was directed against
peptides presented by class I molecules. Having determined
peptide motifs for the class I molecules of the B12 and B15
haplotypes (BF2*1201 and the BF2*1501), we used these
motifs to predict peptides from the VP2 protein sequence
that might bind these class I molecules. We found 12 pep-
tides that fit the B12 peptide motif, but only 2 peptides that
fit the B15 peptide motif (Fig. 2).
From work on mammals (and our own work with these
same chicken class I molecules in a previous study), gener-
ally only a fraction of peptides that fit the simple kind of
motif used here actually bind the class I molecule with
measurable affinity. So, we tested the binding of synthetic
peptides to chicken peripheral blood lymphocytes with an
assay we have used previously (Wallny et al. 2006), a flow
cytometry-based class I stabilisation assay analogous in
procedure to the RMA-S and T2 stabilization assays using
mammalian cells with defective TAP genes. As assessed by
the fluorescence in comparison with no peptide controls,
neither of the two B15 peptides predicted bound to B15 cells,
whereas many of the predicted B12 peptides did bind (Fig. 2).
In addition, we tested the B12 peptides by an assembly
assay, in which B12 heavy chain and β2m were renatured in
the presence of peptide, and the material analysed by size
exclusion chromatography, as illustrated in Fig. 3. Since the
amount of β2m in the assay was far in excess, ratio of the
areas under the peaks of monomer was taken as a measure of
the success of the assembly of heavy chain and β2m depen-
dent on peptide. Ten of the 12 predicted B12 peptides
supported assembly very well, in agreement with the
stabilisation assay (Fig. 2).
Immunisation and challenge show that a peptide
from fp-IBD1 that binds the MHC class I molecule
can confer resistance to IBDV
Having found many peptides from the vaccine fp-IBD1 that
bind BF2*1201, the dominantly expressed class I molecule
from the B12 haplotype, we wanted to test whether
immunisation of C-B12 chickens with one of them would
protect against challenge by IBDV. We had previously de-
veloped a peptide immunisation protocol that protected
against tumour progression after infection of chickens by
Rous sarcoma virus. We used the same protocol of intra-
muscular injection of liposomes loaded with Quil A and
various peptides, in comparison with no immunisation and
with fp-IBD1 immunisation. Three days after challenge with
IBDV strain F52/70, we measured bursal/body weight ratio,
bursal damage score, peak blood viremia and bursal viral
load (Figs. 4 and 5).
As expected, without the challenge infection, chickens
had a normal bursa to body weight ratio, a low bursal
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Fig. 1 Backcross mapping of protection conferred by fp-IBD1 vacci-
nation to bursal damage by IBDV strain F52/70 challenge in two
families derived from line 61 (MHC haplotype B2), CB-12 (B12) and
15I (B15). The graphs represent bursal damages score, with 0 as no
perceptible damage and 5 as extremely damaged (x-axis) against per-
centage birds with that score (y-axis). Upper two panels are birds from
the parental lines 15I and 61, and birds from the backcross family 15I×
F1(15I×61) segregated into the homozygotes and heterozygotes. Low-
er two panels are birds from the parental lines 15I and C-B12, and
birds from the backcross family 15I×F1(15I×C-B12) segregated into
the homozygotes and heterozygotes
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damage score and no virus in the blood or bursa. All four
measures rose after infection without vaccination, as well as
after vaccination with two peptides, the control peptide from
RSV (RSV6) and one of the peptides from fp-IBD1
(IBDV12). In contrast, protection was evident by all
measures after vaccination with fp-IBD1 and even more so
after vaccination with another peptide from fp-IBD1
(IBDV8). Thus, immunisation with a peptide from IBDV
that binds the dominantly expressed class I molecule
BF2*1201 will protect from challenge with a virulent IBDV
(Figs. 4 and 5).
Discussion
In this paper, we have shown that (1) response to a molec-
ular defined vaccine containing the VP2 sequence of IBDV
can be determined by at least two genetic loci, one of which
is the MHC, (2) absence of VP2 peptides that bind the class
I molecule is the basis for the lack of response in a low
responder line and (3) presence of at least one VP2 peptide
that binds the dominantly expressed class I molecule is the
basis for the protection in a high responder line.
The work in this paper grew from earlier observations
(Shaw and Davison 2000) that vaccination with fp-IBD1
could protect some experimental chicken lines and not
others. Examination of the mechanisms of protection
showed that antibody was not involved, which is in accord
with the fact that the VP2 protein as a fusion protein with
β-galactosidase in the vaccine is likely to have a different
three-dimensional structure compared to VP2 protein as a
part of the IBDV capsid. These examinations also showed
that line C-B12 was protected by vaccination with fp-IBD1
but not by the fowlpox virus vector alone, while line 61 was
protected somewhat even by the fowlpox virus vector alone.
In contrast, line 15I was not protected.
Fig. 2 Cell binding and assembly analysis of VP2 peptides predicted
to bind B12 and B15 class I molecules. Left hand panel, mean fluo-
rescence intensities measuring the increase of F21-21 binding to cells
after culture overnight with 1 mM peptide compared to culture over-
night without added peptide. Dotted lines indicate the mean
fluorescence intensities of the cells without incubation with peptides.
Samples were analysed in triplicate, with standard errors well below
10 %. Right hand panel, ratio of the area of peaks corresponding to
assembled monomer compared to β2m from size exclusion chroma-
tography of renaturation assays with indicated peptides
Fig. 3 An example of an assembly assay. Class I heavy chain was
renatured with β2m and peptide IBDV-8, the components separated by
size exclusion chromatography, and the areas under the peaks corre-
sponding to reassembled monomer and free β2m (labelled and indicat-
ed by dashed boxes) determined
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The results in our paper fit with these previous results.
From genetic mapping, line 15I is a low responder with no
protective locus, C-B12 is a high responder with only one
major protective locus (the MHC) and line 61 is a high
responder with two major protective loci (the MHC which
presumably depends on the VP2 fusion protein, and another
locus which may determine response to fowlpox virus vec-
tor alone, perhaps through an innate antiviral response like
inflammation or natural killer cell responses). From our
peptide predictions and peptide vaccination, line 15I is a
low responder because the classical class I molecule
BF2*1501 does not bind peptides from the VP2 sequence,
while line C-B12 is a high responder because the dominant-
ly expressed class I molecule BF2*1201 finds at least one
VP2 peptide (IBDV-8; GNVLVGEGV) that confers
protection to challenge with a virulent IBDV strain. It must
be stressed that IBDV-8 may not be the only peptide that is
responsible for protection, but that there is at least one such
peptide. On the basis of these results, we would predict
(but did not show) that line 61 is a responder because the
dominantly expressed class I molecule BF2*0201 presents
at least one protective IBDV peptide.
Two other interesting points emerged. First, after vacci-
nation with fp-IBD1, the protection of B12/B15 heterozy-
gotes in the backcross was half of that of B12/B12
homozygotes in the original line. This most likely indicates
that the level of peptide bound to BF2*1201 on the surface
of cells is a critical factor in priming the immune response
(as has been shown for mammals, see for example Bullock
et al. 2000), and that the particular conditions of vaccination
are just barely sufficient to protect from the particular con-
ditions of challenge. Second, vaccination with the VP2
peptide IBDV-12 (LAHAIGEGV) did not result in a protec-
tive immune response after vaccination, despite the fact that
this peptide bound well to BF2*1201. There are no
Fig. 4 Means of bursal/body weight ratio (×1,000; upper panel),
bursal damage score (second panel), peak blood viremia (log2Ro; third
panel) and bursal viral load (log2Ro; lower panel) in line C-B12 birds
with no challenge, or after IBDV F52/70 challenge following vaccina-
tion with nothing, fp-IBD1 or different peptides. As an indication of
variability means are shown with their standard errors (though the data
do not conform to the strict requirements of parametric analysis)
Fig. 5 Percentages of line C-B12 birds with different bursal damage
scores after no challenge, or after IBDV F52/70 challenge following
vaccination with nothing, fp-IBD1 or different peptides
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structural differences between IBDV-8 and IBDV-12 which
obviously account for this difference. The protective IBDV-
8 peptide is located in the linker region between the P and S
domains of VP2, while the non-protective binding CB12-
IBDV-12 epitope is located deep in the S domain (Lee et al.
2006) and both peptides are well conserved (indeed identi-
cal in a wide variety of IBDV sequences, including strain
52/70, accession number BAA00745; strain Cu1,
BAA00740; strain STC, BAA00391; strain E/DEL,
CAA38637; strain 23/82, Z21971; strain CT, CAC35470;
strain UK661, CAC60256; strain 88180, CAJ34339; isolate
903/78, AFI55462; isolate SP8, AFN80509). One explana-
tion might be that there is a hole in the T cell repertoire due
to negative selection in the thymus (as has been reported in
mammals, see for example Wölfl et al. 2008).
The previous work (Shaw and Davison 2000) used our
motifs to predict the peptides for the dominantly expressed
class I molecule BF2*0401 from line C-B4 and concluded
in discussion that there were no peptides that would bind,
but nevertheless found that fp-IBD1 conferred the same
level of protection to line C-B4 as line C-B12. One potential
explanation is that another genetic locus in C-B4 is respon-
sible for the protection, but that seems unlikely since C-B4
and C-B12 chickens are taken (as individuals or as annual
sublines) from a C line flock, and so all non-MHC genes
should segregate freely between the lines. Another potential
explanation is that the response is due to the minor gene
BF1*0401, but this gene has virtually undetectable expres-
sion at the level of RNA, protein and antigenic peptide.
Therefore, the most likely explanation for the response of
C-B4 is that the previous work used a very stringent peptide
motif (octamers with Asp2, Asp5 and Glu8, as we published
in Kaufman et al. 1995), but in fact the motif can be
somewhat wider (Wallny et al. 2006). The motif and even
individual peptides show that Glu is also found at positions
2 and 5, and certain hydrophobic amino acids found at a low
level at position 8. Moreover, some peptides may be longer,
and there may be C-terminal overhangs, as we found for
B12 and other haplotypes. In fact, this more relaxed motif
does indeed predict 4 peptides from the VP2 in fp-IBD1.
These results are all in accord with the concept of a
minimal essential MHC (Kaufman et al. 1995, 1999a, b;
Kaufman 2008), in which the structural organisation of
the chicken MHC (compared to most mammals) has
striking effects on function. We have previously shown
that properties of the single dominantly expressed class
I molecule can explain the responses of experimental
chicken lines to RSV and MDV (Wallny et al. 2006;
Koch et al. 2007), and the results in this paper extend
this concept from viral pathogens to viral vaccines.
Moreover, IBDV continues to be a serious threat to
commercial chickens, with both antigenic variation and
increase in virulence reported (reviewed in Ingrao et al.
2013; Mahgoub et al. 2012; Müller et al. 2003, 2012; Schat
and Skinner 2008; van den Berg 2000). While the poultry
industry generally controls IBDV through inactivated vac-
cines that work through class II molecules (which also show
the phenomenon of MHC-determined differences in re-
sponse), some attenuated viral vaccines are used, particularly
in ovo (reviewed in Müller et al. 2012). The likelihood that
some individual chickens remain poorly protected after either
form of vaccination is an unsolved problem. Given that the
MHC of many, if not most, non-mammalian vertebrates have
features first discovered in chickens (reviewed in Kaufman
1999, 2008), it is likely that this is also a problem in other
important contexts, for instance vaccination in some commer-
cial fish (Grimholt et al. 2003) or resistance to citrid fungi in
amphibians (Savage and Zamudio 2011).
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